Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
No holdings reported for quarter Q1 2020 |
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
LEGEND BIOTECH CORP | 11 | Q2 2024 | 10.7% |
VIRIDIAN THERAPEUTICS INC | 11 | Q2 2024 | 6.8% |
VOR BIOPHARMA INC | 11 | Q2 2024 | 5.0% |
ARGENX SE | 10 | Q2 2024 | 8.9% |
IMMUNOCORE HLDGS PLC | 10 | Q1 2024 | 5.9% |
MIRATI THERAPEUTICS INC | 9 | Q4 2023 | 10.9% |
ASCENDIS PHARMA A/S | 9 | Q2 2024 | 10.0% |
ALPINE IMMUNE SCIENCES INC | 9 | Q1 2024 | 3.0% |
ARVINAS INC | 8 | Q2 2024 | 8.7% |
BICYCLE THERAPEUTICS PLC | 8 | Q1 2024 | 5.0% |
View Paradigm Biocapital Advisors LP's complete holdings history.
Latest filings
Type | Filed |
---|---|
N-PX | 2024-08-27 |
13F-HR | 2024-08-14 |
4 | 2024-08-05 |
13F-HR | 2024-05-15 |
SC 13G | 2024-05-02 |
SC 13G | 2024-04-08 |
13F-HR | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
View Paradigm Biocapital Advisors LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.